An Song

An Song has over two decades of work experience in the biotechnology and pharmaceutical industry. They are currently serving as the Chief Development Officer & Head of Preclinical R&D at 4D Molecular Therapeutics since July 2022. Prior to this, An Song held the position of Chief Development Officer (CDO) from September 2021 to August 2022 at the same company.

Before joining 4D Molecular Therapeutics, An Song worked at Immune-Onc Therapeutics from July 2018 to September 2021. During their tenure, they held the roles of Chief Scientific Officer from November 2019 to September 2021, and Senior Vice President Development Sciences from July 2018 to November 2019.

An Song also has a significant tenure at Genentech, starting in 2002. They held various positions at Genentech, including Senior Director from October 2016 to July 2018, and Ocrevus Global Pharmacology Team Leader from October 2012 to May 2017. They also served as a Director and Sr. Scientist from September 2013 to September 2016, Associate Director & Sr Scientist from 2008 to 2013, and Scientist to Sr Scientist from 2002 to 2008.

An Song began their career at Stanford University as a Research Assistant Professor, where they worked from August 2000 to August 2002.

Overall, An Song's work experience showcases their expertise and progressive roles in research, development, and leadership within the biotechnology and pharmaceutical industry.

An Song received a Bachelor's degree in Biochemistry from Nanjing University in 1988. Following this, from 1990 to 1996, they pursued a Doctor of Philosophy (Ph.D.) in Biochemistry and Molecular Biology at Indiana University School of Medicine. After completing their Ph.D., An Song went on to Stanford University for a Postdoctoral Fellowship in Immunology, which they completed from 1996 to 2000.